BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLRX BioLine Rx

Market Closed 10-09 16:00:00 EDT

2.22

+0.01

+0.27%

盘后2.22

+0.000.00%

19:37 EDT

High2.27	Low2.20	Vol9.69K
Open2.20	D1 Closing2.21	Amplitude3.18%
Mkt Cap11.03M	Tradable Cap10.45M	Total Shares4.98M
T/O21.77K	T/O Rate0.21%	Tradable Shares4.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLRX","market":"US","secType":"STK","nameCN":"BioLine Rx","latestPrice":2.216,"timestamp":1791576000000,"preClose":2.21,"halted":0,"volume":9685,"hourTrading":{"tag":"盘后","latestPrice":2.216,"preClose":2.216,"latestTime":"19:37 EDT","volume":171,"amount":383.1107,"timestamp":1791589044803,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0027149321266969357,"floatShares":4716500,"shares":4978216,"eps":-1.5822,"marketStatus":"Market Closed","change":0.006,"latestTime":"10-09 16:00:00 EDT","open":2.2,"high":2.2703,"low":2.2,"amount":21772.8862715,"amplitude":0.03181,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.5822,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":2.21,"preHourTrading":{"tag":"盘前","latestPrice":2.28,"preClose":2.21,"latestTime":"04:06 EDT","volume":605,"amount":1384.259965,"timestamp":1791533183900,"change":0.07,"changeRate":0.031674,"amplitude":0.027149},"postHourTrading":{"tag":"盘后","latestPrice":2.216,"preClose":2.216,"latestTime":"19:37 EDT","volume":171,"amount":383.1107,"timestamp":1791589044803,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5461507180100538,"impliedVol":1.8884,"impliedVolPercentile":0.4223},"requestUrl":"/m/hq/s/BLRX","defaultTab":"news","newsList":[{"id":"2663686077","title":"Israel's BioLineRx Q2 Net Loss Widens on Higher R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663686077","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663686077?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:09","pubTimestamp":1788174543,"startTime":"0","endTime":"0","summary":"Israel's BioLineRx Q2 net loss widens on higher R&DexpensesOverviewIsrael biopharma's Q2 revenue was flat yr/yr at $0.3 mlnNet loss widened to $4.3 mln from $3.9 mln on higher R&D and admin expensesCo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BLRX","BK4139","01228","01477","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663607207","title":"BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2663607207","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663607207?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:01","pubTimestamp":1788174105,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $294.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 41.20 percent.  This is a 3.29 percent decrease over sales of $304.000 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61516810/bioline-rx-q2-sales-294-000k-miss-500-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077540","title":"Press Release: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077540","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077540?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:00","pubTimestamp":1788174000,"startTime":"0","endTime":"0","summary":"maintaining its cash runway guidance into the first half of 2027.-- On August 27, 2026, the Company entered into a definitive agreement for. an offering with gross proceeds of $3.75 million, expected to close on or. about August 31, 2026.Development UpdatesGLIX1 in GBM-- In July, dosing commenced in the second of five planned cohorts in the. Phase 1 dose escalation part of the Phase 1/2a study.-- Three leading cancer centers are enrolling patients in the Phase 1. part of the study: NYU Langone Health, led by Dr. Alexandra. Miller; Northwestern University, led by Dr. Roger Stupp and Dr.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5TLWC47.USD","BK4195","MTD","PFS","BK4139","BK4567","BK4121","LU1721428933.USD","IE00BYQQ9H92.USD","LU2413666426.HKD","LU2211817866.USD","BK4548","LU1093756168.USD","LU1093756325.SGD","BK4533","LU0347712357.USD","IE00BFXG0V08.USD","BK4211","BK4588","LU2413666699.HKD","PDX","BK4585","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662509829","title":"BioLine RX Ltd Expected to Post Breakeven Results a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2662509829","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662509829?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:32","pubTimestamp":1787920328,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd <BLRX.OQ> expected to post breakeven results a share - Earnings PreviewBioLine RX LtdBLRX.OQ,BLRX.Ois expected to  show a rise in quarterly revenue when it reports  results on August 31 for the period ending March 31 2026The Modiin Central-based  company is expected to report a 87.1% increase in revenue to $477 thousand from $255 thousand a year ago, according to the estimate from one analyst, based on LSEG data.LSEG's mean analyst estimate for BioLine RX Ltd is for breakeven results per share.The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for BioLine RX Ltd is $23.00, about 733.3% above its last closing price of $2.76This summary was machine generated August 28 at 12:32 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL8N44P0VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649998244","title":"BioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2649998244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649998244?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:25","pubTimestamp":1783509921,"startTime":"0","endTime":"0","summary":"BioLineRx (BLRX) announced new preclinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in a patient-derived xenograft model...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biolinerx-hemispherian-announces-new-preclinical-data-on-glix1-parp-inhibitor-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biolinerx-hemispherian-announces-new-preclinical-data-on-glix1-parp-inhibitor-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943372","title":"JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943372?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:41","pubTimestamp":1780404070,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh reiterated a Buy rating on Bioline RX Ltd Sponsored ADR today and set a price target of $12.00. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-bioline-rx-ltd-sponsored-adr-blrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-bioline-rx-ltd-sponsored-adr-blrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294332","title":"Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines (ONC) and Autonomix Medical, Inc. (AMIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640294332?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:41","pubTimestamp":1780404062,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-beone-medicines-onc-and-autonomix-medical-inc-amix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-beone-medicines-onc-and-autonomix-medical-inc-amix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMIX","LU0128526141.USD","ONC","HCSG","BLRX","BK4137","BK4585","XBI","BK4588","BK4139","LABU","BK4581","LU0029874061.USD","BK4082","XLV","BK4526","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638500504","title":"BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2638500504","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638500504?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:02","pubTimestamp":1779879777,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent.  This is a 87.06 percent increase over sales of $255.000 thousand","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52801859/bioline-rx-q1-sales-477-000k-beat-343-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638048955","title":"Press Release: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2638048955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638048955?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma  -. - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide -resistant patient-derived xenograft model -. - Management to host conference call today, May 27, at 8:30 am EDT -. TEL AVIV, Israel, May 27, 2026 /PRNewswire/ -- BioLineRx Ltd.  , a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2026, and provided a corporate update.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721428933.USD","PDX","R","BK4211","BK4232","BK4195","CDX","BK4548","IE00BYQQ9H92.USD","PFS","LU0347712357.USD","LU2413666426.HKD","LU2211817866.USD","BK4533","BK4585","BK4139","BK4567","MTD","BK4022","BLRX","LU2413666699.HKD","LU1093756325.SGD","IE00B5TLWC47.USD","IE00BFXG0V08.USD","BK4588","BK4121","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638558357","title":"BioLine RX Ltd  expected to post a loss of $1.04 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2638558357","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638558357?lang=en_us&edition=fundamental","pubTime":"2026-05-25 20:32","pubTimestamp":1779712322,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of $1.04 a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a rise in quarterly revenue when it reports  results on May 27 for the p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nL8N4220HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636516853","title":"BioLineRx and Hemispherian report new GLIX1 anti-tumor effect in GBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2636516853","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636516853?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:13","pubTimestamp":1779189198,"startTime":"0","endTime":"0","summary":"BioLineRx (BLRX) and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, announced highly encouraging ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biolinerx-and-hemispherian-report-new-glix1-anti-tumor-effect-in-gbm-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biolinerx-and-hemispherian-report-new-glix1-anti-tumor-effect-in-gbm-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AS","BK4202","BLRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306705","title":"BioLine Rx Q4 EPADS $(0.34) Beats $(0.54) Estimate, Sales $194.000K Miss $651.598K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306705","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306705?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:06","pubTimestamp":1774357604,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.54) by 37.04 percent.  The company reported quarterly sales of $194.000 thousand which missed the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51430236/bioline-rx-q4-epads-0-34-beats-0-54-estimate-sales-194-000k-miss-651-598k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770568","title":"BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770568","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770568?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:16","pubTimestamp":1774264582,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent.  This is a 98.35 percent decrease over sales of $11.749 million","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51401341/bioline-rx-q4-sales-194-000k-miss-651-598k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621772207","title":"Press Release: BioLineRx Reports 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2621772207","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621772207?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263600,"startTime":"0","endTime":"0","summary":"- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma  by end of this month -. - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms -. - Management to host conference call today, March 23, at 8:30 am EDT -. TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd.  , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4585","MTD","BK4139","BK4533","BK4195","SCD","BK4548","BLRX","IE00BFXG0V08.USD","ASH","LU0347712357.USD","BK4211","LU1093756325.SGD","LU2211817866.USD","BK4121","BK4109","PFS","BK4567","LU2413666699.HKD","LU1721428933.USD","LU2413666426.HKD","IE00BYQQ9H92.USD","BK4588","IE00B5TLWC47.USD","LU2463526074.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739374","title":"BioLine RX Ltd  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739374","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739374?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:02","pubTimestamp":1774011739,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of77cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a fall in quarterly revenue when it reports  results on March 23 for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N408197:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620478831","title":"Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2620478831","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620478831?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:45","pubTimestamp":1773989100,"startTime":"0","endTime":"0","summary":"BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/20/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/20/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372528/top-wall-street-forecasters-revamp-biolinerx-expectations-ahead-of-q4-earnings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372528/top-wall-street-forecasters-revamp-biolinerx-expectations-ahead-of-q4-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BLRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620422172","title":"BioLine RX Ltd  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422172","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422172?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:43","pubTimestamp":1773751400,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of77cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a fall in quarterly revenue when it reports  results  for the period en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL8N40514T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biolinerx.com","stockEarnings":[{"period":"1week","weight":-0.065},{"period":"1month","weight":-0.131},{"period":"3month","weight":-0.2828},{"period":"6month","weight":-0.0323},{"period":"1year","weight":-0.4699},{"period":"ytd","weight":-0.2}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.072241},{"month":2,"riseRate":0.4,"avgChangeRate":-0.047168},{"month":3,"riseRate":0.2,"avgChangeRate":-0.102622},{"month":4,"riseRate":0.4,"avgChangeRate":-0.016375},{"month":5,"riseRate":0.6,"avgChangeRate":0.112777},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.040987},{"month":7,"riseRate":0.466667,"avgChangeRate":0.017518},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.052202},{"month":9,"riseRate":0.375,"avgChangeRate":-0.024877},{"month":10,"riseRate":0.3125,"avgChangeRate":-0.020876},{"month":11,"riseRate":0.266667,"avgChangeRate":-0.053503},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.069939}],"exchange":"NASDAQ","name":"BioLine Rx","nameEN":"BioLine Rx","securityTypeName":"DR","adrRate":"1:600"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioLine Rx,BLRX,BioLine Rx股票,BioLine Rx股票老虎,BioLine Rx股票老虎国际,BioLine Rx行情,BioLine Rx股票行情,BioLine Rx股价,BioLine Rx股市,BioLine Rx股票价格,BioLine Rx股票交易,BioLine Rx股票购买,BioLine Rx股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction